JP2024516970A5 - - Google Patents

Info

Publication number
JP2024516970A5
JP2024516970A5 JP2023564682A JP2023564682A JP2024516970A5 JP 2024516970 A5 JP2024516970 A5 JP 2024516970A5 JP 2023564682 A JP2023564682 A JP 2023564682A JP 2023564682 A JP2023564682 A JP 2023564682A JP 2024516970 A5 JP2024516970 A5 JP 2024516970A5
Authority
JP
Japan
Prior art keywords
approximately
antibody
cancer
composition according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/028189 external-priority patent/WO2022236134A1/en
Publication of JP2024516970A publication Critical patent/JP2024516970A/ja
Publication of JP2024516970A5 publication Critical patent/JP2024516970A5/ja
Pending legal-status Critical Current

Links

JP2023564682A 2021-05-07 2022-05-06 抗il-27抗体及びその使用 Pending JP2024516970A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163185989P 2021-05-07 2021-05-07
US63/185,989 2021-05-07
US202163203688P 2021-07-28 2021-07-28
US63/203,688 2021-07-28
US202163277035P 2021-11-08 2021-11-08
US63/277,035 2021-11-08
PCT/US2022/028189 WO2022236134A1 (en) 2021-05-07 2022-05-06 Anti-il-27 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024516970A JP2024516970A (ja) 2024-04-18
JP2024516970A5 true JP2024516970A5 (https=) 2025-05-15

Family

ID=81928149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564682A Pending JP2024516970A (ja) 2021-05-07 2022-05-06 抗il-27抗体及びその使用

Country Status (11)

Country Link
US (1) US12577299B2 (https=)
EP (1) EP4334348A1 (https=)
JP (1) JP2024516970A (https=)
KR (1) KR20240005809A (https=)
AU (1) AU2022270170A1 (https=)
CA (1) CA3215856A1 (https=)
IL (1) IL308198A (https=)
JO (1) JOP20230282A1 (https=)
MX (1) MX2023013149A (https=)
TW (1) TW202304981A (https=)
WO (1) WO2022236134A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025539147A (ja) * 2022-11-22 2025-12-03 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ebv駆動性bリンパ増殖性疾患の処置のためのil-27アンタゴニストの使用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Pd−1アンタゴニストおよび感染性疾患を処置するための方法
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2648752B1 (en) * 2010-12-06 2017-02-15 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
AU2012205384B2 (en) * 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
KR20230020023A (ko) 2018-03-14 2023-02-09 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
CN112512571B (zh) * 2018-03-22 2025-02-07 表面肿瘤学有限责任公司 抗il-27抗体及其用途
MX2022003719A (es) * 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.

Similar Documents

Publication Publication Date Title
US20180036395A1 (en) Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies
CN113768933B (zh) Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
TWI818120B (zh) 藉由免疫檢查點阻礙藥與folfirinox療法之併用的癌症治療
JP2020508317A5 (https=)
JP6410795B2 (ja) カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物
EP4257609A1 (en) Combination therapies based on pd-1 inhibitors and sik3 inhibitors
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
WO2020032231A1 (ja) 免疫チェックポイント阻害薬の有効性を予測するためのバイオマーカー
JP2022549854A5 (https=)
Li et al. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo
CN111973747A (zh) 用于联合治疗卵巢癌的喹啉衍生物
JP2024516970A5 (https=)
CN114728000A (zh) 治疗癌症的新型药物组合
WO2021046250A1 (en) Methods of treatment
TW202005651A (zh) 波齊替尼(poziotinib)與抗her1、her2或her4抗體之組合及使用彼之方法
CN101175495B (zh) 抗癌化合物的组合
Dong et al. Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors
US20180333415A1 (en) Therapeutic methods
Huang et al. Molecular targeting of growth factor receptor signaling in radiation oncology
WO2019096233A1 (zh) 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途
WO2025047922A1 (ja) 3,5-二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬を含む癌治療法
WO2025064744A1 (en) Tyra-300 (5-[(1r)-1-(3,5-dichloro-4-pyridyl)ethoxy]-3-[6-(2-methylsulfonyl-2,6-diazaspiro[3.3]heptan-6-yl)-3-pyridyl]-1h-indazole ) in combination with a pd-1 or pd-l1 antagonist for use in the treatment of cancer
WO2026020109A1 (en) Combination treatment comprising a fgfr3 inhibitor and a pd-1/pd-l1 inhibitor for use in the treatment of cancer
KR20260062972A (ko) 3,5-2치환 벤젠알키닐 화합물과 면역 체크 포인트 저해약을 포함하는 암치료법
CN116490244A (zh) Sting激动剂、检查点抑制剂和辐射的施用